Skip to content
Screener

Rigel Pharmaceuticals RIGL REZLIDHIA — Payment of cost share to collaboration partner

Similar metrics at other companies

Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share
$5.33B-8.0%
Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share, current
$1.02B+4.8%
Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share, five years
$215M-26.1%
Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share, four years
$273M-27.6%
Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share, three years
$655M-3.7%
Raytheon Technologies logo
RTXCommercial Aerospace — Collaboration partner share, two years
$854M-16.3%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$750.37M+25.0%
Enterprise value$794.27M+44.9%
P/E2.1×-4.1×
P/S2.5×+0.3×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept rigl:PaymentOfCostShareToCollaborationPartner.

The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:05 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001034842-26-000032

We have a Strategic Collaboration Agreement with MDACC entered in December 2023 to evaluate olutasidenib in AML and other hematologic cancers. Under the agreement, we are obligated to provide study materials and up to $15.0 million in time-based milestone payments over the five-year collaboration term, unless terminated earlier. Through March 31, 2026, we have provided $5.3 million in funding to MDACC.

Item 1. Financial Statements

FAQ

What is Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner?
Rigel Pharmaceuticals (RIGL) reported REZLIDHIA — payment of cost share to collaboration partner of $1.33M in Q4 2026.
How has Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner changed year-over-year?
Rigel Pharmaceuticals's REZLIDHIA — payment of cost share to collaboration partner decreased by 0.0% year-over-year, from $1.33M to $1.33M.
What does REZLIDHIA — payment of cost share to collaboration partner mean?
This metric tracks the cash outflows related to the reimbursement or sharing of development, commercialization, or operational expenses with a collaboration partner for REZLIDHIA. It quantifies the company's commitment to shared cost structures defined in joint venture or licensing contracts. Analyzing these payments helps investors assess the efficiency of the partnership and the impact of shared expenses on product-level profitability.

Ask your AI about Rigel Pharmaceuticals's rezlidhia — payment of cost share to collaboration partner.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude